Genfit S.A. (GNFT)
$4.68
Rating:
Recommendation:
-
| Symbol | GNFT |
|---|---|
| Price | $4.68 |
| Beta | 1.321 |
| Volume Avg. | 0.03M |
| Market Cap | 233.137M |
| Shares () | - |
| 52 Week Range | 3.01-6.38 |
| 1y Target Est | - |
| DCF Unlevered | GNFT DCF -> | |
|---|---|---|
| DCF Levered | GNFT LDCF -> | |
| ROE | -63.53% | Strong Sell |
| ROA | -9.41% | Neutral |
| Operating Margin | - | |
| Debt / Equity | 136.55% | Buy |
| P/E | 3.69 | Buy |
| P/B | 1.67 | Strong Buy |
Latest GNFT news
About
Download (Excel)Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.